These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9519785)

  • 1. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.
    Aparicio A; Gardner A; Tu Y; Savage A; Berenson J; Lichtenstein A
    Leukemia; 1998 Feb; 12(2):220-9. PubMed ID: 9519785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide.
    Ural AU; Yilmaz MI; Avcu F; Pekel A; Zerman M; Nevruz O; Sengul A; Yalcin A
    Int J Hematol; 2003 Dec; 78(5):443-9. PubMed ID: 14704038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells.
    Takahashi R; Shimazaki C; Inaba T; Okano A; Hatsuse M; Okamoto A; Hirai H; Ashihara E; Nakagawa M
    Leuk Res; 2001 Jan; 25(1):77-83. PubMed ID: 11137564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma.
    Gordon S; Helfrich MH; Sati HI; Greaves M; Ralston SH; Culligan DJ; Soutar RL; Rogers MJ
    Br J Haematol; 2002 Nov; 119(2):475-83. PubMed ID: 12406088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment.
    Derenne S; Amiot M; Barillé S; Collette M; Robillard N; Berthaud P; Harousseau JL; Bataille R
    J Bone Miner Res; 1999 Dec; 14(12):2048-56. PubMed ID: 10620064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.
    Vorotnjak M; Boos J; Lanvers-Kaminsky C
    Anticancer Drugs; 2004 Sep; 15(8):795-802. PubMed ID: 15494642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.
    Reinholz GG; Getz B; Pederson L; Sanders ES; Subramaniam M; Ingle JN; Spelsberg TC
    Cancer Res; 2000 Nov; 60(21):6001-7. PubMed ID: 11085520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonate therapy in multiple myeloma: past, present, future.
    Jantunen E
    Eur J Haematol; 2002; 69(5-6):257-64. PubMed ID: 12460229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates induce apoptosis in human breast cancer cell lines.
    Senaratne SG; Pirianov G; Mansi JL; Arnett TR; Colston KW
    Br J Cancer; 2000 Apr; 82(8):1459-68. PubMed ID: 10780527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
    Shipman CM; Rogers MJ; Apperley JF; Russell RG; Croucher PI
    Br J Haematol; 1997 Sep; 98(3):665-72. PubMed ID: 9332325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates induce breast cancer cell death in vitro.
    Fromigue O; Lagneaux L; Body JJ
    J Bone Miner Res; 2000 Nov; 15(11):2211-21. PubMed ID: 11092402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic growth inhibition of YM529 with biologic response modifiers (BRMs) in myeloma cells.
    Yata K; Otsuki T; Yamada O; Wada H; Yawata Y; Sugihara T
    Int J Hematol; 2002 Jun; 75(5):534-9. PubMed ID: 12095156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines.
    Tassone P; Forciniti S; Galea E; Morrone G; Turco MC; Martinelli V; Tagliaferri P; Venuta S
    Leukemia; 2000 May; 14(5):841-4. PubMed ID: 10803515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the biology and treatment of myeloma bone disease.
    Berenson JR
    Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S16-20. PubMed ID: 11757204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.
    Kunzmann V; Bauer E; Feurle J; Weissinger F; Tony HP; Wilhelm M
    Blood; 2000 Jul; 96(2):384-92. PubMed ID: 10887096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate treatment inhibits the growth of prostate cancer cells.
    Lee MV; Fong EM; Singer FR; Guenette RS
    Cancer Res; 2001 Mar; 61(6):2602-8. PubMed ID: 11289137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.
    Baulch-Brown C; Molloy TJ; Yeh SL; Ma D; Spencer A
    Leuk Res; 2007 Mar; 31(3):341-52. PubMed ID: 16996129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.